

364

Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* \* \* \* \* Welcome to STN International \* \* \* \* \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock  
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area  
NEWS 4 Apr 09 ZDB will be removed from STN  
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB  
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS  
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER  
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available  
NEWS 9 Jun 03 New e-mail delivery for search results now available  
NEWS 10 Jun 10 MEDLINE Reload  
NEWS 11 Jun 10 PCTFULL has been reloaded  
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment  
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;  
saved answer sets no longer valid  
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY  
NEWS 15 Jul 30 NETFIRST to be removed from STN  
NEWS 16 Aug 08 CANCERLIT reload  
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN  
NEWS 18 Aug 08 NTIS has been reloaded and enhanced  
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)  
now available on STN  
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded  
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded  
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced  
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced  
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file  
NEWS 25 Sep 16 CA Section Thesaurus available in CAPLUS and CA  
NEWS 26 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985  
NEWS 27 Oct 21 EVENTLINE has been reloaded  
NEWS 28 Oct 24 BEILSTEIN adds new search fields  
NEWS 29 Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN  
NEWS 30 Oct 25 MEDLINE SDI run of October 8, 2002  
NEWS 31 Nov 18 DKLIT has been renamed APOLLIT  
NEWS 32 Nov 25 More calculated properties added to REGISTRY  
NEWS 33 Dec 02 TIBKAT will be removed from STN  
NEWS 34 Dec 04 CSA files on STN  
NEWS 35 Dec 17 PCTFULL now covers WP/PCT Applications from 1978 to date  
NEWS 36 Dec 17 TOXCENTER enhanced with additional content  
NEWS 37 Dec 17 Adis Clinical Trials Insight now available on STN  
NEWS 38 Dec 30 ISMEC no longer available  
NEWS 39 Jan 13 Indexing added to some pre-1967 records in CA/CAPLUS  
NEWS 40 Jan 21 NUTRACEUT offering one free connect hour in February 2003  
NEWS 41 Jan 21 PHARMAML offering one free connect hour in February 2003  
NEWS 42 Jan 29 Simultaneous left and right truncation added to COMPENDEX,  
ENERGY, INSPEC

NEWS 43 Feb 13 CANCERLIT is no longer being updated  
NEWS 44 Feb 24 METADEX enhancements  
NEWS 45 Feb 24 PCTGEN now available on STN  
NEWS 46 Feb 24 TEMA now available on STN  
NEWS 47 Feb 26 NTIS now allows simultaneous left and right truncation  
NEWS 48 Feb 26 PCTFULL now contains images  
NEWS 49 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results  
NEWS 50 Mar 19 APOLLIT offering free connect time in April 2003  
NEWS 51 Mar 20 EVENTLINE will be removed from STN

NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,  
CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),  
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 10:33:43 ON 24 MAR 2003

FILE 'REGISTRY' ENTERED AT 10:33:53 ON 24 MAR 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 MAR 2003 HIGHEST RN 500280-37-5  
DICTIONARY FILE UPDATES: 23 MAR 2003 HIGHEST RN 500280-37-5

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.


Crossover limits have been increased. See **HELP CROSSOVER** for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>  
Uploading 09849400.str

## L1 STRUCTURE UPLOADED

=> d 11  
L1 HAS NO ANSWERS  
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> S 11  
SAMPLE SEARCH INITIATED 10:34:17 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 27 TO ITERATE

100.0% PROCESSED 27 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
PROJECTED ANSWERS: 0 TO 0  
PROJECTED ITERATIONS: 229 TO 851  
BATCH \*\*COMPLETE\*\*

L2 0 SEA SSS SAM L1

=> s 11 sss full  
FULL SEARCH INITIATED 10:34:25 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 610 TO ITERATE

100.0% PROCESSED 610 ITERATIONS 11 ANSWERS  
SEARCH TIME: 00.00.01

L3 11 SEA SSS FUL L1

=> file caplus	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	146.15	148.36

FILE 'CAPLUS' ENTERED AT 10:34:35 ON 24 MAR 2003  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Mar 2003 VOL 138 ISS 13  
 FILE LAST UPDATED: 23 Mar 2003 (20030323/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13  
 L4 20 L3

=> d 14 fbib hitstr abs total

L4 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2003 ACS  
 AN 2003:118638 CAPLUS  
 DN 138:153540

TI Preparation of aminobutylphenothiazines, -iminodibenzyls, and related compounds as chemosensitizing agents against chloroquine resistant plasmodium falciparum

IN Lin, Ai J.; Guan, Jian; Kyle, Dennis E.; Milhous, Wilbur K.

PA USA

SO U.S. Pat. Appl. Publ., 27 pp.  
 CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003032801	A1	20030213	US 2001-849400	20010507
				US 2001-849400	20010507

OS MARPAT 138:153540


IT 443309-35-1P, 10-(4-Pyrrolidin-1-ylbutyl)phenothiazine  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compd.; prepn. of aminobutylphenothiazines, -iminodibenzyls, and related compds. as chemosensitizing agents against chloroquine

resistant plasmodium falciparum)  
 RN 443309-35-1 CAPLUS  
 CN 10H-Phenothiazine, 10-[4-(1-pyrrolidinyl)butyl]- (9CI) (CA INDEX NAME)



GI



I

AB Title compds. [I; X = (substituted) alkyl, heteroatom; n = 4-6; Y = (substituted) alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, NR1R2; R1, R2 = H, heteroatom, (substituted) alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl; each ring structure may be substituted], were prepd. Thus, 10-(4-pyrrolidin-1-ylbutyl)phenothiazine (general prepn. given) at 50 ng/mL completely restored the sensitivity of TM91C235 cells to chloroquine.

L4 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2003 ACS

AN 2002:868744 CAPLUS

DN 137:370096

TI Tricyclic N-(aminoalkyl)-substituted phenothiazines, iminodibenzyls, iminostilbenes, and diphenylamines, active as chemosensitizing agents against chloroquine-resistant Plasmodium falciparum, and methods of making and using thereof

IN Lin, Ai J.; Guan, Jian; Kyle, Dennis E.; Milhous, Wilbur K.

PA United States Army Medical Research and Material Command, USA

SO PCT Int. Appl., 66 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002089810	A1	20021114	WO 2001-US14574	20010507
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,				

HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

WO 2001-US14574 20010507

OS MARPAT 137:370096


IT 443309-35-1P, 10-[4-(Pyrrolidin-1-yl)butyl]phenothiazine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; prepn. of phenothiazines, iminodibenzyls, iminostilbenes, and diphenylamines as antimalarial sensitizing agents for treatment of multidrug-resistant malaria with chloroquine and mefloquine)

RN 443309-35-1 CAPLUS

CN 10H-Phenothiazine, 10-[4-(1-pyrrolidinyl)butyl]- (9CI) (CA INDEX NAME)



GI




AB Title compds. I and pharmaceutically acceptable salts or prodrugs thereof are disclosed [wherein: X is a substituted or unsubstituted alkyl, a heteroatom, or 2 H atoms; n is 4, 5, or 6; Y is a substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, or NR1R2; wherein R1 and R2 are each independently, H, a heteroatom, substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and wherein each ring structure is independently substituted or unsubstituted]. Also disclosed are chemosensitizing agents and methods of modulating, attenuating, reversing, or affecting a cell's or organism's resistance to a given drug such as an antimalarial. In particular, a group of compds. I were prep'd. and shown to have improved anti-MDR


(multidrug resistance) efficacy and reduced side effects (no data) in restoration of the clin. efficacy of antimalarials including mefloquine and chloroquine. Four of the compds. also showed moderate intrinsic antimalarial activity in the absence of chloroquine or mefloquine. Structure-activity relationships, e.g., regarding alkyl chain length, ring rigidity, and amino terminal size, are discussed. For instance, 4-chloro-1-butanol was converted to the THP ether (99%) and then used to N-alkylate phenothiazine (46%), followed by deprotection (100%), conversion of the resultant alc. to a chloride with  $\text{SOCl}_2$  (62%), and amination of the chloride (34%) to give the pyrrolidine deriv. II. At 50 ng/mL in vitro, II completely restored the sensitivity of TM91C235 cells [a highly drug-resistant malaria isolate from Thailand] to chloroquine, giving 99% cell growth suppression/inhibition. When tested on a different clone of *Plasmodium falciparum*, II gave superior MDR-reversing activity, with a fractional inhibitory concn. (FIC) of 0.21, using a 1:1 combination of chloroquine and II.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 20 CAPLUS COPYRIGHT 2003 ACS  
 AN 2002:372411 CAPLUS  
 DN 137:109247  
 TI Design, Synthesis, and Evaluation of New Chemosensitizers in Multi-Drug-Resistant *Plasmodium falciparum*  
 AU Guan, Jian; Kyle, Dennis E.; Gerena, Lucia; Zhang, Quan; Milhous, Wilbur K.; Lin, Ai J.  
 CS Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, MD, 20910, USA  
 SO Journal of Medicinal Chemistry (2002), 45(13), 2741-2748  
 CODEN: JMCMAR; ISSN: 0022-2623  
 PB American Chemical Society  
 DT Journal  
 LA English  
 OS CASREACT 137:109247  
 IT 443309-35-1P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (prepn. of antimalarial drug chemosensitizing aminoalkyl phenothiazines, benzazepines, and diphenylamines)  
 RN 443309-35-1 CAPLUS  
 CN 10H-Phenothiazine, 10-[4-(1-pyrrolidinyl)butyl]- (9CI) (CA INDEX NAME)



GI




AB A series of new chemosensitizers (modulators) against chloroquine-resistant *Plasmodium falciparum* were designed and synthesized in an attempt to prep. modulators with enhancing drug-resistant reversing efficacy and minimal side effects. Phenothiazine, iminodibenzyl, and iminostilbene arom. amine ring systems I ( $X = S, CH_2CH_2, CH:CH; n = 4-6$ ;  $R_1, R_2 = Me, Et, PhCH_2; R_1R_2N = pyrrolinyl$ ) and diphenylamines II ( $R_1 = R_2 = Et, R_1R_2N = pyrrolinyl$ ) were examd. Various tertiary amino groups including either noncyclic or cyclic aliph. amines were introduced to explore the steric tolerance at the end of the side chain. The new compds. showed better drug-resistant reversing activity in chloroquine-resistant than in mefloquine-resistant cell lines and were generally more effective against chloroquine-resistant *P. falciparum* isolates from Southeast Asian (W2 and TM91C235) than those from South America (PC49 and RCS). Structure-activity relationship studies revealed that elongation of the alkyl side chain of the mol. retained the chemosensitizing activity, and analogs with four-carbon side chains showed superior activity. Furthermore, new modulators with phenothiazine ring exhibited the best chemosensitizing activity among the four different ring systems examd. Terminal amino function has limited steric tolerance as evidenced by the dramatic lose of the modulating activity, when the size of substituent at the amino group increases. The fractional inhibitory concn. (FIC) index of the best new modulator I ( $X = S, n = 4, R_1R_2N = pyrrolinyl$ ) is 0.21, which is superior to that of verapamil (0.51), one of the best-known multi-drug-resistant reversing agents. Some of the analogs displayed moderate intrinsic in vitro antimalarial activity against a W-2 clone of *P. falciparum*.

RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2003 ACS  
AN 2000:4293 CAPLUS  
DN 132:273829  
TI Relationship between cytotoxic activity and dipole moment for phthalimido- and chloroethyl-phenothiazines  
AU Kurihara, Teruo; Motohashi, Noboru; Sakagami, Hiroshi; Molnar, Joseph  
CS Faculty of Science, Josai University, Saitama, 350-0295, Japan  
SO Anticancer Research (1999), 19(5B), 4081-4083  
CODEN: ANTRD4; ISSN: 0250-7005  
PB International Institute of Anticancer Research  
DT Journal  
LA English  
IT 180388-70-9 180388-72-1 180388-74-3  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(relationship between cytotoxic activity and dipole moment for phthalimido- and chloroethyl-phenothiazines)

RN 180388-70-9 CAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[4-(10H-phenothiazin-10-yl)butyl]- (9CI)  
(CA INDEX NAME)


RN 180388-72-1 CAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[4-(2-chloro-10H-phenothiazin-10-yl)butyl]- (9CI) (CA INDEX NAME)



RN 180388-74-3 CAPLUS


CN 1H-Isoindole-1,3(2H)-dione, 2-[4-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]butyl]- (9CI) (CA INDEX NAME)




AB Among twelve phenothiazine-related compds., the cytotoxic activity of six "half-mustard type" phenothiazines was significantly higher than that of six phthalimido compds. 1-(2-Chloroethyl)-3-(2-chloro-10H-phenothiazin-10-yl)propylurea, 1-(2-chloroethyl)-3-(2-chloro-10H-phenothiazin-10-yl)butylurea and 1-(2-chloroethyl)-3-(2-trifluoromethyl-10H-phenothiazin-10-yl)butylurea showed the highest cytotoxic activity, in parallel with high  $\Delta\mu$  (difference between two dipole moments,  $\mu_g$  and  $\mu_e$ ). There was also pos. relation between cytotoxic activity and MO energy such as  $\pi$ -LUMO,  $\pi$ -HOMO, and lone pair orbitals originated from O, N1, and N3 atoms. The present study demonstrated that cytotoxic activity of "half-mustard type" phenothiazines can be predicted by their dipole moments and MO energies.

RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2003 ACS  
 AN 1999:654667 CAPLUS  
 DN 132:131770  
 TI Chemical structure and tumor type specificity of "half-mustard type" phenothiazines  
 AU Motohashi, Noboru; Kurihara, Teruo; Sakagami, Hiroshi; Szabo, Diana; Csuri, Klara; Molnar, Joseph  
 CS Department of Medicinal Chemistry, Meiji Pharmaceutical University, Tokyo, 204-8588, Japan  
 SO Anticancer Research (1999), 19(3A), 1859-1864  
 CODEN: ANTRD4; ISSN: 0250-7005  
 PB International Institute of Anticancer Research  
 DT Journal  
 LA English  
 IT 180388-70-9 180388-72-1 180388-74-3  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (chem. structure-activity and tumor-type specificity of half-mustard type phenothiazines)  
 RN 180388-70-9 CAPLUS  
 CN 1H-Isoindole-1,3(2H)-dione, 2-[4-(10H-phenothiazin-10-yl)butyl]- (9CI) (CA INDEX NAME)



RN 180388-72-1 CAPLUS  
CN 1H-Isoindole-1,3(2H)-dione, 2-[4-(2-chloro-10H-phenothiazin-10-yl)butyl]-(9CI) (CA INDEX NAME)




RN 180388-74-3 CAPLUS  
CN 1H-Isoindole-1,3(2H)-dione, 2-[4-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]butyl]-(9CI) (CA INDEX NAME)



AB The antiproliferative activity of six half-mustard type phenothiazines against a total of 54 tumor cell lines: 4 leukemia, 9 non-small-cell lung, 7 colon-, 5 CNS-, 8 melanoma, 6 ovarian-, 8 renal-, 1 prostate and 6 breast cancer was detd. by NCI-Information Intensive-Approach. The C-2 position of phenothiazines were substituted with H, Cl and CF<sub>3</sub> groups. The half-mustard and ring system was linked either by a propylene or a butylene bridge. Colon-cancer cell showed the highest sensitivity against half-mustard type phenothiazines, followed by leukemia, melanoma, prostate-, CNS-, breast-, lung-, renal and ovarian cancer cells. These data suggest the cancer-type-specific antitumor action of half-mustard type phenothiazines.


RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2003 ACS  
 AN 1998:282099 CAPLUS  
 DN 129:75984  
 TI The primary in vitro anticancer activity of "half-mustard type" phenothiazines in NCI's revised anticancer screening paradigm  
 AU Wuonola, Mark A.; Palfreyman, Michael G.; Motohashi, Noboru; Kawase, Masami; Gabay, Sabit; Gupta, Radha Raman; Molnar, Joseph  
 CS Scriptgen Pharmaceuticals, Inc., Medford, MA, 02155, USA  
 SO Anticancer Research (1998), 18(1A), 337-348  
 CODEN: ANTRD4; ISSN: 0250-7005  
 PB Anticancer Research  
 DT Journal  
 LA English  
 IT 180388-70-9 180388-72-1 180388-74-3  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (primary in vitro anticancer activity of "half-mustard type" phenothiazines in NCI's revised anticancer screening paradigm)  
 RN 180388-70-9 CAPLUS  
 CN 1H-Isoindole-1,3(2H)-dione, 2-[4-(10H-phenothiazin-10-yl)butyl]- (9CI)  
 (CA INDEX NAME)




RN 180388-72-1 CAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[4-(2-chloro-10H-phenothiazin-10-yl)butyl]-  
(9CI) (CA INDEX NAME)



RN 180388-74-3 CAPLUS


CN 1H-Isoindole-1,3(2H)-dione, 2-[4-[2-(trifluoromethyl)-10H-phenothiazin-10-  
yl]butyl]- (9CI) (CA INDEX NAME)




AB Some new phenothiazines have been synthesized on the basis of previous studies. The anticancer activity of "half-mustard type" phenothiazines was investigated on sixty different cancer cell lines *in vitro*. The percentage of growth (PG), 50% inhibition of growth (GI50), the tumor growth inhibition (TGI) and the concn. required for 50% lethality of cells (IC50) were examd. and calcd. in the presence of various (from 10-4 to 10-8 M) concns. of phenothiazine alkylurea derivs. The following cell lines were involved in the study: 6 leukemia, 9 non-small-cell lung cancer, 7 colon cancer, 6 central nervous system cancer, 8 melanoma, 6 ovarian cancer, 8 renal cancer, 2 prostate and 8 breast cancer cell lines. The anti-leukemic activity of four chloroethyl-substituted phenothiazine-alkylureas was shown by considerable growth inhibition, in the 10-5 M range, of the six different leukemia cell lines. The 50% inhibition of growth was nearly the same for the four compds. on all cell lines. Tumor growth inhibition (TGI) and IC50 value to cells varied from -4.0 to -4.66. The two derivs. with the butylene bridge were more effective than propylene linked compds. against the CCRP-CEM, HL60 (TB), K-562 and MOLT-4 cell lines. However, the anti-leukemic activity of the derivs. was nearly the same for RPMT 8226 and SR cell lines. The substituent at the 2- position of phenothiazine ring and the length of the linker between the side chain nitrogen and the phenothiazine ring system are apparently important for antileukemic activity. Four of the 9 non-small-cell lung cancer cell lines were sensitive, while the other 5 cell lines were not. The compds. had a slight growth inhibitory effect on colon cell carcinoma and melanoma cells in which case the butylene linker seemed to be more effective than the propylene linker. At the same time, all of the compds. were weak or mostly inactive on cancer cells from the central nervous system. One ovarian cancer line of the 6, the IGROVI was sensitive to butylurea phenothiazines, however, the other five were not sensitive at all. The difference in the sensitivity of various renal cell carcinomas was significant: 5 lines were not sensitive, three of them (786-0, RXF-393 and TK-10) were sensitive to only butylene-substituted phenothiazine-ureas, propylene substitution resulted in ineffective compds. The compds. were not able to inhibit the 2 prostate and 4 breast cancer cell lines, even at 10-4 M. It was interesting that propylene-linked ureas were more effective than butylene-linked derivs. on MCF-7, but butylene-linked derivs. were more effective than propylene-linked compds. on MDA MB-231 and MDA-N. In addn., MDA MB 435 was more sensitive to the trifluoromethyl derivs. than the compds. without this substituent. Since the phthalimido-alkyl phenothiazines were not

active at the first level of prescreen, these compds. were omitted from this study. The drug sensitivity of some cancer cell lines was not uniform for the different groups, therefore we postulate that the resistance can be related to some kind of (existing) drug-efflux mechanism. Apparently, the tumor specificity of phenothiazine alkylureas is more related to the leukemia specificity of alkylureas than to any CNS or lung specificity of phenothiazines.

L4 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2003 ACS  
 AN 1998:200671 CAPLUS  
 DN 128:265747  
 TI Correlation between structure and diverse biological activities of "half-mustard type" phenothiazines  
 AU Motohashi, Noboru; Kurihara, Teruo; Satoh, Kazue; Sakagami, Hiroshi; Molnar, Joseph  
 CS Department of Medicinal Chemistry, Meiji College of Pharmacy, Tokyo, 188, Japan  
 SO Anticancer Research (1997), 17(6D), 4403-4406  
 CODEN: ANTRD4; ISSN: 0250-7005  
 PB Anticancer Research  
 DT Journal  
 LA English  
 IT 180388-70-9 180388-72-1 180388-74-3  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (correlation between structure and diverse biol. activities of half-mustard type phenothiazines in relation to dipole moments and radical generation)  
 RN 180388-70-9 CAPLUS  
 CN 1H-Isoindole-1,3(2H)-dione, 2-[4-(10H-phenothiazin-10-yl)butyl] - (9CI) (CA INDEX NAME)




RN 180388-72-1 CAPLUS  
 CN 1H-Isoindole-1,3(2H)-dione, 2-[4-(2-chloro-10H-phenothiazin-10-yl)butyl] - (9CI) (CA INDEX NAME)



RN 180388-74-3 CAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[4-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]butyl] - (9CI) (CA INDEX NAME)



AB The structure and activity relation of fifteen "half-mustard type" phenothiazines and related compds. were investigated. These compds. did not show any direct bactericidal activity, possibly due to the lack of radical generation activity. Pretreatment with phenothiazines significantly reduced the lethality of *Escherichia coli* GN2411 infection, possibly due to activation of the host defense mechanism. Higher concns. of these compds. showed cytotoxic activity against several cultured tumor cell lines. However, no clear-cut relation was established between biol. activity and two dipole moments (.mu.g, .mu.e).

L4 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2003 ACS


AN 1998:49717 CAPLUS

DN 128:162543

TI Drug resistance reversal, antimutagenicity and antiretroviral effect of phthalimido- and chloroethyl-phenothiazines

AU Motohashi, Noboru; Kurihara, Teruo; Kawase, Masami; Hever, Aniko; Tanaka, Masaru; Szabo, Diana; Nacsá, János; Yamanaka, Wataru; Kerim, Ablikim;


Molnar, Joseph  
 CS Department of Medicinal Chemistry, Meiji College of Pharmacy, Tanashi,  
 188, Japan  
 SO Anticancer Research (1997), 17(5A), 3537-3543  
 CODEN: ANTRD1; ISSN: 0250-7005  
 PB Anticancer Research  
 DT Journal  
 LA English  
 IT 180388-72-1, 1H-Isoindole-1,3(2H)-dione, 2-[4-(10H-phenothiazin-10-yl)butyl]-  
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or  
 effector, except adverse); BSU (Biological study, unclassified); PRP  
 (Properties); BIOL (Biological study)  
 (drug resistance reversal, antimutagenicity and antiretroviral effect  
 of phthalimido- and chloroethyl-phenothiazines)  
 RN 180388-72-1 CAPLUS  
 CN 1H-Isoindole-1,3(2H)-dione, 2-[4-(2-chloro-10H-phenothiazin-10-yl)butyl]-  
 (9CI) (CA INDEX NAME)




AB The effect of substituted phenothiazines was studied in three different systems; bacteria and cancer cells and reverse transcriptase enzyme of Moloney leukemia virus. F'lac and hemolysin plasmids were eliminated by some substituted phenothiazines from E. coli at a very low frequency. The same phenothiazine derivs. also were synergistic with tetracycline in bacteria and shown antimutagenic effect in Ames test. No mutagenic effects were obsd. in TA 98 strain of *Salmonella typhimurium*. Chloroethyl-substituted phenothiazines showed antimutagenicity equiv. to the parent compds.; however, phthalimido-substituted phenothiazines had higher antimutagenicity of 50%. P-glycoprotein responsible for multidrug resistance was also inhibited in tumor cells. The accumulation of the fluorescent rhodamine 123 in the phenothiazine treated multidrug resistant tumor cells was measured by flow cytometry. Some of the substituted phenothiazines were effective P-glycoprotein blockers, while some compds. had moderate activity, but others were without effect as compared to 5  $\mu$ M verapamil. On the basis of computer anal. there are some correlations between the biol. activities and the dipole moments, and entropy of the studied mols. Our results suggest that the inhibition of Hly+ plasmid replication and P-glycoprotein function may depend partly on similar electronic properties of the studied phenothiazine derivs. The

activity of Moloney leukemia virus reverse transcriptase was inhibited by the substituted phenothiazines, however, no basic differences were found in the activities of phthalimido- and chloroethyl substituted phenothiazines.

L4 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2003 ACS  
 AN 1998:49699 CAPLUS  
 DN 128:175800  
 TI The in vitro antitumor assay of "half-mustard type" phenothiazines in screens of AIDS-related leukemia and lymphomas  
 AU Wuonola, Mark A.; Palfreyman, Michael G.; Motohashi, Noboru; Kawase, Masami; Gabay, Sabit; Molnar, Joseph  
 CS SCRIPTGEN Pharmaceuticals, Inc., Medford, MA, 02155, USA  
 SO Anticancer Research (1997), 17(5A), 3425-3429  
 CODEN: ANTRD4; ISSN: 0250-7005  
 PB Anticancer Research  
 DT Journal  
 LA English  
 IT 180388-70-9, D 681648 180388-72-1, D 681650  
 180388-74-3, D 681652  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (in vitro antitumor assay of half-mustard type phenothiazines in screens of AIDS-related leukemia and lymphomas in relation to structure)  
 RN 180388-70-9 CAPLUS  
 CN 1H-Isoindole-1,3(2H)-dione, 2-[4-(10H-phenothiazin-10-yl)butyl] - (9CI) (CA INDEX NAME)




RN 180388-72-1 CAPLUS  
 CN 1H-Isoindole-1,3(2H)-dione, 2-[4-(2-chloro-10H-phenothiazin-10-yl)butyl] - (9CI) (CA INDEX NAME)



RN 180388-74-3 CAPLUS


CN 1H-Isoindole-1,3(2H)-dione, 2-[4-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]butyl] (9CI) (CA INDEX NAME)




AB Twelve different "half-mustard type" phenothiazines were newly synthesized and tested on seven AIDS-related lymphoma (ARL) tumor cell lines, one leukemia CCRF-CEM cell culture and five different lymphoma lines; RL, KD488, AS283, PA682 and SU-DHL-7 cell lines. The alkylene-urea substituted phenothiazines affected the growth and inhibited the growth rate of AIDS-related lymphoma cells. The Cl-substituent at the 2-position was more effective than the CF<sub>3</sub> substitution. In AIDS-related leukemia, also the compds. with Cl at the 2-position with propylene or butylene linkers, -(CH<sub>2</sub>)<sub>3</sub>- and -(CH<sub>2</sub>)<sub>4</sub>-, resp., were more effective than the CF<sub>3</sub> substituted compds. Two of the six phenothiazine-substituted alkyl-urea derivs., i.e., 1-(2-chloroethyl)-3-(2-chloro-10H-phenothiazin-10-yl)propyl-1-urea (GI<sub>50</sub>=-5.66, TGI=-5.04) and 1-(2-chloroethyl)-3-(2-chloro-10H-phenothiazin-10-yl)butyl-1-urea (GI<sub>50</sub>=-5.61, TGI=-5.12) exhibited antitumor activity for AIDS-related leukemia and five AIDS-related lymphomas. The trifluoromethyl-substituted derivs. were not as effective on AIDS-related tumor cell lines. Apparently, the substituent at the 2-position on the phenothiazine and the alkylene no. of the linker

attached to the nitrogen of the phenothiazine ring have an important role in the compd.'s antitumor effects on AIDS-related leukemia and lymphomas.

L4 ANSWER 10 OF 20 CAPLUS COPYRIGHT 2003 ACS  
 AN 1998:49698 CAPLUS  
 DN 128:162631  
 TI The primary in vitro antitumor screening of "half-mustard type" phenothiazines  
 AU Wuonola, Mark A.; Palfreyman, Michael G.; Motohashi, Noboru; Kawase, Masami; Gabay, Sabit; Nacsá, János; Molnar, Joseph  
 CS SCRIPTGEN Pharmaceuticals, Inc., Medford, MA, 02155, USA  
 SO Anticancer Research (1997), 17(5A), 3409-3423  
 CODEN: ANTRD4; ISSN: 0250-7005  
 PB Anticancer Research  
 DT Journal  
 LA English  
 IT 180388-70-9, D 681648 180388-72-1, D 681650  
 180388-74-3, D 681652  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
 (the primary in vitro antitumor screening of "half-mustard type" phenothiazines)  
 RN 180388-70-9 CAPLUS  
 CN 1H-Isoindole-1,3(2H)-dione, 2-[4-(10H-phenothiazin-10-yl)butyl] - (9CI) (CA INDEX NAME)




RN 180388-72-1 CAPLUS  
 CN 1H-Isoindole-1,3(2H)-dione, 2-[4-(2-chloro-10H-phenothiazin-10-yl)butyl] - (9CI) (CA INDEX NAME)



RN 180388-74-3 CAPLUS


CN 1H-Isoindole-1,3(2H)-dione, 2-[4-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]butyl] - (9CI) (CA INDEX NAME)




AB The antitumor effects of "half-mustard-type" phenothiazines were studied on 57 different tumor cell lines, including leukemias, non-small lung cancer, colon, central nervous system, ovarian, renal, breast, and prostate cancer, as well as melanoma cell cultures. Alkyl-urea derivs. of phenothiazines displayed in vitro antitumor activity. The phenothiazine phthalimido derivs. (1-6) were not active on the majority of cancer cell cultures. In contrast, propylureas (9, 11) were active against some leukemia cell types. Only two compds. with the butylene [(CH2)4] linker (10, 12) were active against non-small lung cancer cells. Compds. contg. the propylene linker were less effective. On colon cancer lines, tumor cells from the central nervous system and on melanoma cells the same compds. were effective, however, having substituents at the 2-position of phenothiazine seems to be important. Surprisingly, the majority of ovarian cancer cell lines (except one type, IGROVI) and five of eight renal cancer lines were not sensitive to these phenothiazine derivs. The two butylene linked phenothiazine ureas (10, 12) had moderate antiproliferative action on two renal cancer cell lines. The prostate

cancer and some breast cancer cell lines were not sensitive. Nevertheless some breast cancer cell lines were apparently sensitive to CF3-substituted phenothiazine alkylureas. On the basis of these expts. one may postulate that in the case of insensitive cells an mdr-gene encoded multidrug resistance efflux pump is responsible for the resistance. The selectivity or organ cell specificity of the effective phenothiazines will be targeted for improvement in further studies, in order to avoid the general cytotoxic effects of "half mustard type" phenothiazines.

L4 ANSWER 11 OF 20 CAPLUS COPYRIGHT 2003 ACS  
 AN 1996:703922 CAPLUS  
 DN 126:26380  
 TI Synthesis and antitumor activity of 1-[2-(chloroethyl)-3-(2-substituted-10H-phenothiazin-10-yl)alkyl]-1-ureas as potent anticancer agents  
 AU Motohashi, Noboru; Kawase, Masami; Kurihara, Teruo; Hever, Aniko; Nagy, Szilvia; Ocsocvszki, Imre; Tanaka, Masaru; Molnar, Joseph  
 CS Department Medicinal Chemistry, Meiji College Pharmacy, Tanashi, 188, Japan  
 SO Anticancer Research (1996), 16(5A), 2525-2532  
 CODEN: ANTRD4; ISSN: 0250-7005  
 PB Anticancer Research  
 DT Journal  
 LA English  
 IT 180388-70-9P 180388-72-1P 180388-74-3P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (synthesis and antitumor activity of [(chloroethyl)(substituted-phenothiazinyl)alkyl]ureas in relation to structure)  
 RN 180388-70-9 CAPLUS  
 CN 1H-Isoindole-1,3(2H)-dione, 2-[4-(10H-phenothiazin-10-yl)butyl]- (9CI) (CA INDEX NAME)




RN 180388-72-1 CAPLUS  
 CN 1H-Isoindole-1,3(2H)-dione, 2-[4-(2-chloro-10H-phenothiazin-10-yl)butyl]- (9CI) (CA INDEX NAME)



RN 180388-74-3 CAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[4-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]butyl]-(9CI) (CA INDEX NAME)



AB 10-[N-(Phthalimido)alkyl]-2-substituted-10H-phenothiazines and 1-(2-chloroethyl)-3-(2-substituted-10H-phenothiazin-10-yl)alkyl-1-ureas were synthesized and found to have antiproliferative effects on human HEp-2 and L5178Y cell cultures. The multi-drug resistant subline of mouse lymphoma was sensitive to the reversal effects of some 10-[N-(phthalimido)alkyl]-2-substituted-10H-phenothiazines, while 1-(2-chloro-ethyl)-3-(2-substituted-10H-phenothiazin-10-yl)alkyl-1-ureas were less effective but had a similar degree of antiproliferative effect on both cell lines.

L4 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2003 ACS

AN 1996:518725 CAPLUS

DN 125:211824


TI Antitumor activity of phenothiazine-related compounds

AU Nagy, Sylvia; Argyelan, George; Molnar, Joseph; Kawase, Masami; Motohashi, Noboru


CS Faculty Medicine, Albert Szent-Gyorgyi Medical University, Szeged, H-6720,

Hung.


SO Anticancer Research (1996), 16(4A), 1915-1918  
 CODEN: ANTRD4; ISSN: 0250-7005  
 PB Anticancer Research  
 DT Journal  
 LA English  
 IT 180388-70-9 180388-72-1 180388-74-3  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (phenothiazine deriv. antitumor activity)  
 RN 180388-70-9 CAPLUS  
 CN 1H-Isoindole-1,3(2H)-dione, 2-[4-(10H-phenothiazin-10-yl)butyl]- (9CI)  
 (CA INDEX NAME)



RN 180388-72-1 CAPLUS  
 CN 1H-Isoindole-1,3(2H)-dione, 2-[4-(2-chloro-10H-phenothiazin-10-yl)butyl]- (9CI) (CA INDEX NAME)




RN 180388-74-3 CAPLUS  
 CN 1H-Isoindole-1,3(2H)-dione, 2-[4-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]butyl]- (9CI) (CA INDEX NAME)




AB One of the biggest challenges in health care is the fight against tumors. Some phenothiazines have antitumor activity on HEp-2 tumor cells. In this study, we tested the antitumor effects of three series such as 10-nonsubstituted phenothiazines, 10-[n-(phthalimido)alkyl]-2-substituted-10H-phenothiazines and 1-(chloroethyl)-3-(2-substituted-10H-phenothiazin-10-yl)alkyl-1-ureas with H, Cl and CF<sub>3</sub> substitution at position C2. The TCID<sub>50</sub> of phenothiazines was affected by the H, Cl and CF<sub>3</sub> at C2. The trifluoromethyl deriv. of phenothiazine showed potent (R = CF<sub>3</sub>, TCID<sub>50</sub> = 4.7 .mu.g) activity, whereas the chlorine deriv. of phenothiazine (R = Cl, TCID<sub>50</sub> = 62.5 .mu.g) had a relatively weak effect. In the group of 10-[n-(phthalimido)alkyl]-2-substituted-10H-phenothiazines, 10-[3-(phthalimido)propyl]-10H-phenothiazine (R = H, n = 3, TCID<sub>50</sub> = 11.5 .mu.g), 10-[4-(phthalimido)butyl]-10H-phenothiazine (R = H, n = 4, TCID<sub>50</sub> = 7.8 .mu.g) and 10-[3-(phthalimido)propyl]-2-trifluoromethyl-10H-phenothiazine (R = CF<sub>3</sub>, n = 3, TCID<sub>50</sub> = 11.5 .mu.g) were very effective. On the other hand, TCID<sub>50</sub> of 10-[3-(phthalimido)propyl]-2-chloro-10H-phenothiazine (R = Cl, n = 3, TCID<sub>50</sub> = 75.0 .mu.g), 10-[4-(phthalimido)butyl]-2-chloro-10H-phenothiazine (R = Cl, n = 4, TCID<sub>50</sub> = 31.3 .mu.g) and 10-[4-(phthalimido)butyl]-2-trifluoromethyl-10H-phenothiazine (R = CF<sub>3</sub>, n = 4, TCID<sub>50</sub> = 50.0 .mu.g) were about 4-8 times less effective than 10-[4-(phthalimido)butyl]-10H-phenothiazine (R = H, n = 4, TCID<sub>50</sub> = 7.8 .mu.g). Among six 1-(chloroethyl)-3-(2-substituted-10H-phenothiazin-10-yl)alkyl-1-ureas, two chlorine compds. such as 1-(2-chloroethyl)-3-(2-chloro-10H-phenothiazin-10-yl)propyl-1-urea (R = Cl, n = 3, TCID<sub>50</sub> = 6.3 .mu.g), 1-(2-chloroethyl)-3-(2-chloro-10H-phenothiazin-10-yl)butyl-1-urea (R = Cl, n = 4, TCID<sub>50</sub> = 7.8 .mu.g), and 1-(2-chloroethyl)-3-(2-trifluoromethyl-10H-phenothiazin-10-yl)butyl-1-urea (R = CF<sub>3</sub>, n = 4, TCID<sub>50</sub> = 7.8 .mu.g) were significantly active. Tests showed that the substitution at 2C position apparently affected the anti-HEp-2 tumor cell activity; that the length of the aliph. side chain at 10N contributes to the anti-tumor activity; and that the TCID<sub>50</sub> values of the derivs. with a butylene group (-C<sub>4</sub>H<sub>8</sub>-) were lower than those with propylene group (-C<sub>3</sub>H<sub>6</sub>-) except 10-[4-(phthalimido)butyl]-2-trifluoromethyl-10H-phenothiazine and 1-(2-chloroethyl)-3-(2-chloro-10H-phenothiazin-10yl)butyl-1-urea.

L4 ANSWER 13 OF 20 CAPLUS COPYRIGHT 2003 ACS  
 AN 1996:472497 CAPLUS  
 DN 125:211925

TI Immunomodulating activities on cellular cytotoxicity and the blast transformation of human lymphocytes by 10-n-(phthalimido) alkyl-2-substituted-10H-phenothiazines and 1-(2-chloroethyl)-3-(2-substituted-10H-phenothiazin-10-yl)alkyl-1-ureas  
 AU Petri, Ildiko B.; Szekeres, Eva; Varga, Eva; Berek, Imre; Molnar, Joseph; Berek, Livia; Kawase, Masami; Motohashi, Noboru  
 CS Blood Transfusion Centre, Albert Szent-Gyorgyi Medical University, Szeged, H-6720, Hung.  
 SO Anticancer Research (1996), 16(3A), 1247-1250  
 CODEN: ANTRD4; ISSN: 0250-7005  
 PB Anticancer Research  
 DT Journal  
 LA English  
 IT 180388-70-9 180388-72-1 180388-74-3  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (immunomodulating activities on cellular cytotoxicity and blast transformation of human lymphocytes by)  
 RN 180388-70-9 CAPLUS  
 CN 1H-Isoindole-1,3(2H)-dione, 2-[4-(10H-phenothiazin-10-yl)butyl]- (9CI) (CA INDEX NAME)




RN 180388-72-1 CAPLUS  
 CN 1H-Isoindole-1,3(2H)-dione, 2-[4-(2-chloro-10H-phenothiazin-10-yl)butyl]- (9CI) (CA INDEX NAME)



RN 180388-74-3 CAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[4-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]butyl]-(9CI) (CA INDEX NAME)



AB Phenothiazines, 10-n-(phthalimido)alkyl-2-substituted-10H-phenothiazines, and 1-(2-chloroethyl)-3-(2-substituted-10H-phenothiazin-10-yl)alkyl-1-ureas were investigated for their effects on antibody-dependent cellular cytotoxicity (ADCC), natural killer (NK) cells and the blast transformation of human peripheral blood mononuclear cells. All of the compds. dose-dependently suppressed mitogen stimulated T cell proliferation. In contrast, a strong enhancing effect on NK cell activity was detected mostly in the case of 1-(2-chloroethyl)-3-(2-substituted-10H-phenothiazin-10-yl)alkyl-10-ureas and their related compds. The stimulating effect directly influenced the NK cells and was demonstrated at all tested concns.


L4 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2003 ACS

AN 1996:239126 CAPLUS


DN 124:332043

TI Induction of DNA fragmentation in human myelogenous leukemic cell lines by phenothiazine-related compounds


AU Sakagami, Kiroshi; Takahashi, Hideo; Yoshida, Hiroshi; Yamamura, Mitsuhsisa; Fukuchi, Kunihiiko; Gomi, Kunihide; Motohashi, Noboru; Takeda, Minoru  
 CS School Medicine, Showa University, Tokyo, 142, Japan  
 SO Anticancer Research (1995), 15(6B), 2533-40  
 CODEN: ANTRD4; ISSN: 0250-7005  
 PB Anticancer Research  
 DT Journal  
 LA English  
 IT 176657-40-2 176657-42-4 176657-44-6  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
 (induction of DNA fragmentation in human myelogenous leukemic cell lines by phenothiazine-related compds.)  
 RN 176657-40-2 CAPLUS  
 CN 2,5-Pyrrolidinedione, 1-[4-(10H-phenothiazin-10-yl)butyl]- (9CI) (CA INDEX NAME)



RN 176657-42-4 CAPLUS  
 CN 2,5-Pyrrolidinedione, 1-[4-(2-chloro-10H-phenothiazin-10-yl)butyl]- (9CI) (CA INDEX NAME)



RN 176657-44-6 CAPLUS  
 CN 2,5-Pyrrolidinedione, 1-[4-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]butyl]- (9CI) (CA INDEX NAME)



AB A series of phenothiazine, benzo[a]phenothiazine and benz[c]acridine derivs. were compared for their ability to induce nucleosome-sized DNA fragmentation (a biochem. hallmark of apoptosis), using agarose gel electrophoresis and a fluorescence activated cell sorter. Significant DNA fragmentation-inducing activity was detected in 12H-benzo[a]phenothiazine, 5-oxo-5H-benzo[a]phenothiazine and 9-methyl-12H-benzo[a]phenothiazine, which induced the monocytic differentiation of human myelogenous leukemic cell lines. On the other hand, an other three benzo[a]phenothiazines, six 10-[n-(phthalimido)alkyl]2-substituted-10H-phenothiazines, six 1-(2-chloroethyl)-3-(2-substituted-10H-phenothiazin-10-yl)alkyl-1-ureas, and twelve benz[c]acridines showed little or no DNA fragmentation-inducing activity. Active benzo[a]phenothiazines induced DNA fragmentation in four human myelogenous leukemic cell lines (HL-60, ML-1, U-937, THP-1), but not in human T-cell leukemic MOLT-4 and erythroleukemic K-562 cell lines, which were also resistant to other apoptosis-inducing agents. Ca<sup>2+</sup>-depletion from the culture medium did not significantly affect their DNA fragmentation-inducing activity. The differentiation and apoptosis-inducing activity of benzo[a]phenothiazines have an important role for their medicinal efficacy.

L4 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2003 ACS

AN 1962:483298 CAPLUS

DN 57:83298

OREF 57:16630g-i,16631a-d

TI Dimethylaminophenothiazines

IN Craig, Paul N.

PA Smith Kline & French Laboratories

SO 4 pp.

DT Patent

LA Unavailable


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI US 3047572 19620731 US 19581210

IT 95138-82-2, Phenothiazine, 2-(dimethylamino)-10-[4-(1-pyrrolidinyl)butyl]-(prepn. of)

RN 95138-82-2 CAPLUS

CN Phenothiazine, 2-(dimethylamino)-10-[4-(1-pyrrolidinyl)butyl]-(7CI) (CA INDEX NAME)




AB The title compds. were prep'd. and found useful as tranquilizers, calmatives, antiemetics, and general central nervous system depressants. 4-Bromo-3-nitrodimethylaniline (84 g.) in 600 ml. alc. treated with an aq. alc. soln. of Na o-bromothiophenol, the mixt. refluxed 20 hrs., and the product crystd. gave 2'-bromo-2-nitro-4-dimethylaminodiphenyl sulfide (I), m. 120-1.degree. (alc.). I (91.9 g.) in 690 ml. concd. HCl treated with 235 g. SnCl<sub>2</sub>, refluxed 4 hrs., made alk., and the mixt. extd. with hot C<sub>6</sub>H<sub>6</sub> gave 2'-bromo-2-amino-4-dimethylaminodiphenyl sulfide (II), m. 126-7.degree. II (49.5 g.), 28.8 g. anhyd. K<sub>2</sub>CO<sub>3</sub>, 8 g. CuI, and 2.88 g. Cu bronze powder refluxed 500 ml. HCONMe<sub>2</sub> gave 2-dimethylaminophenoxythiazine (III), m. 157-8.degree.; HBr salt was made. III (19.5 g.) in 700 ml. xylene treated 80 min. under reflux with 4 g. NaNH<sub>2</sub>, then refluxed 6 hrs. with 12.4 g. 3-chloro-1-dimethylaminopropane in 50 ml. xylene, extd. with AcOH, neutralized, and taken up in C<sub>6</sub>H<sub>6</sub> gave 10-(3-dimethylaminopropyl)-2-dimethylaminophenoxythiazine, b0.3-0.5 215-20.degree.; di-HCl salt m. 214-15.degree.. III (24.2 g.) and 2.4 g. LiNH<sub>2</sub> in 100 ml. PhMe refluxed 1 hr., then 7 hrs. under N with 16.3 g. 2-chloro-1-diethylaminopropane gave 10-(diethylaminoisopropyl)-2-dimethylaminophenoxythiazine; a maleic acid salt was obtained. III (48.4 g.) and 8.3 g. NaNH<sub>2</sub> in 500 ml. xylene refluxed 1.5 hrs. under N, then 5 hrs. with 41.8 g. 3-chloro-2-methyl-1-(N-methylpiperazinyl)propane gave 10-[2-methyl-1-(N-methylpiperazinyl)propyl]-2-dimethylaminophenoxythiazine; HBr salt was made. III (12.1 g.) in 500 ml. xylene and 1.2 g. LiNH<sub>2</sub> refluxed 2 hrs., then 5 hrs. with 10.4 g. 1-formyl-4-(3-chloropropyl)piperazine in 100 ml. xylene gave 10-(3-N-formylpiperazinyl)propyl)-2-dimethylaminophenoxythiazine (IV) as an oil. IV (38.7 g.) in 200 ml. alc. and 125 ml. H<sub>2</sub>O contg. 30 ml. 40% NaOH refluxed 2 hrs. gave 10-(3'-piperazinylpropyl)-2-dimethylaminophenoxythiazine (V) as an oil. V (55.2 g.), 19.6 g.  $\beta$ -bromoethanol, and 21.6 g. K<sub>2</sub>CO<sub>3</sub> in 700 ml. PhMe refluxed 6 hrs. gave 10-(3-(N- $\beta$ -hydroxyethylpiperazinyl)propyl)-2-dimethylaminophenoxythiazine (VI); acetate prep'd. VI (20.6 g.) in 300 ml. C<sub>6</sub>H<sub>6</sub> and 4 g. AcCl left 10 hrs. at room temp. and the oily base treated with ethereal HCl gave 10-[3-( $\beta$ -acetoxyethylpiperazinyl)propyl]-2-dimethylaminophenoxythiazine-HCl. V (18.4 g.), 8.8 g. 2-bromo-2'-hydroxyethyl ether, and 7.6 g. K<sub>2</sub>CO<sub>3</sub> in 500 ml. xylene refluxed 15 hrs. gave 10-[3-(N-hydroxyethoxyethylpiperazinyl)propyl]-2-dimethylaminophenoxythiazine; tartrate salt prep'd. III (60.5 g.) and 10.1 g. NaNH<sub>2</sub> in 800 ml. xylene refluxed with gradual addn. of 55.6 g. 4-bromo-1-N-pyrrolidinylbutane gave 10-[4-(N-pyrrolidinylbutyl)]-2-dimethylaminophenoxythiazine; bismethylenesalicylate salt prep'd. V (11 g.) in 50 ml. HCONMe<sub>2</sub> treated with 7.5 g. p-nitrophenethyl bromide in 10 ml. HCONMe<sub>2</sub>, stirred 6 hrs. at 95-105.degree., poured into 1600 ml. H<sub>2</sub>O, the mixt. made alk., extd. with CHCl<sub>3</sub>, washed, filtered, and evapd. gave 10-[3-(p-nitrophenethylpiperazinyl)propyl]-2-dimethylaminophenoxythiazine (VII). VII

(11.7 g.) in 300 ml. alc. and 0.3 g. PtO<sub>2</sub> hydrogenated 1 hr. at 50 lb./sq. in. gave 10-[3-(p-aminophenethylpiperazinyl)propyl]-2-dimethylaminophenothiazine.

L4 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2003 ACS  
 AN 1961:8225 CAPLUS  
 DN 55:8225  
 OREF 55:1667a-c  
 TI Basic alkylthioalkyl esters of phenothiazine-10-carboxylic acid and their salts  
 IN Myers, Gorden S.; Davis, Martin A.  
 PA American Home Products Corp.  
 DT Patent  
 LA Unavailable  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2951077		19600830	US	
IT	112745-72-9, 10H-1,3-Dioxolo[4,5-b]phenothiazine, 10-[4-(1-pyrrolidinyl)butyl]- (prepn. of)				
RN	112745-72-9	CAPLUS			
CN	10H-1,3-Dioxolo[4,5-b]phenothiazine, 10-[4-(1-pyrrolidinyl)butyl]- (6CI) (CA INDEX NAME)				




AB The title compds. were bacteriostatic agents. A soln. of beta.-(diethylaminoethylthio)ethanol in 50 ml. pyridine was added to 26.1 g. phenothiazine-10-carboxylic acid-chloride in 50-ml. dry pyridine. The mixt. was maintained at room temp. during addn. (20 min.), heated 30 min. at 25-90.degree., then for another 45 min. at 90.degree., cooled, and poured onto 400 ml. ice water. 2-(Diethylaminoethylthio)ethyl phenothiazine-10-carboxylate (I) was liberated from soln. by adding NaOH. I was extd. with ether, and washed with water repeatedly till free from pyridine. Evapn. of the solvent gave I as a dark oil. The citrate of I was prep'd. by treating an ethereal soln. of I with an equal wt. of citric acid in acetone, m. 99-101.degree. (decompn.). Similarly were obtained: I.MeBr, m. 155-60.degree. (decompn.); 2-(dimethylaminoethylthio)ethyl phenothiazine-10-carboxylate maleate, m. 106-9.degree.; 2-(diisopropylaminoethylthio)ethyl phenothiazine-10-carboxylate citrate, m. 49-54.degree..

L4 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2003 ACS  
 AN 1961:8224 CAPLUS  
 DN 55:8224

OREF 55:1666f-i,1667a  
 TI Methyleneoxy-substituted phenothiazines  
 IN Gordon, Maxwell  
 PA Smith, Kline & French Laboratories  
 DT Patent  
 LA Unavailable  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2945031		19600712	US	
IT	112745-72-9	10H-1,3-Dioxolo[4,5-b]phenothiazine, 10-[4-(1-pyrrolidinyl)butyl]- (prepn. of)			
RN	112745-72-9	CAPLUS			
CN	10H-1,3-Dioxolo[4,5-b]phenothiazine, 10-[4-(1-pyrrolidinyl)butyl]- (6CI) (CA INDEX NAME)				




AB 6-Bromopiperonal (I) (m. 127-8.5.degree.) was prep'd. from 300 g. piperonal and 120 ml. Br in 900 ml. HOAc. I (210 g.) was added in small portions to 1400 ml. concd. HNO<sub>3</sub> while the temp. was kept at 25.degree. and the mixt. then decompd. with ice H<sub>2</sub>O to give 4-nitro-5-bromocatechol methylene ether (II), m. 88-9.degree.. A soln. of Na o-bromothiophenol (from 113.4 g. o-bromothiophenol, 500 ml. EtOH, 23.9 g. NaOH, and 25 ml. H<sub>2</sub>O) was added dropwise to 147.6 g. II in 1250 ml. hot EtOH, the mixt. refluxed 3 hrs., cooled, and filtered to give 4,5-methylenedioxy-2-nitro-2'-bromodiphenyl sulfide (III), m. 149-50.degree.. III (186 g.) was reduced with 426.6 g. SnCl<sub>2</sub> and 675 ml. concd. HCl in 675 ml. EtOH to 2-amino-4,5-methylenedioxy-2'-bromodiphenyl sulfide (IV), m. 142-3.5.degree.. IV (3.6 g.), 1.56 g. anhyd. K<sub>2</sub>CO<sub>3</sub>, and 0.2 g. Cu powder in 45 ml. HCONMe<sub>2</sub> was refluxed 6 hrs., filtered, and the filtrate dild. with H<sub>2</sub>O to ppt. 2,3-methylenedioxyphenothiazine (V), m. 202-3.5.degree.. V (24.3 g.) and 2.4 g. LiNH<sub>2</sub> in 100 ml. dry toluene was refluxed 3 hrs., 13.3 g. 3-chloro-1-dimethylaminopropane in 10 ml. toluene added, the mixt. refluxed an addnl. 4 hrs., and from this mixt. an oil, 10-(3-dimethylaminopropyl)-2,3-methylenedioxyphenothiazine, isolated. 2,3-Methylenedioxyphenothiazines with the following substituents were also prep'd.: 10-(diethylaminoisopropyl), 10-[2-methyl-1-(N-methylpiperazinyl)propyl], 10-[3-(N-formylpiperazinyl)propyl], 10-(3-piperazinylpropyl), 10-[3-[N-(.beta.-hydroxyethyl)piperazinyl]propyl], 10-[3-(N-acetoxyethylpiperazinyl)propyl], 10-[3-[N-(hydroxyethoxyethyl)piperazinyl]propyl], 10-(4-pyrrolidinylbutyl), 10-[3-[N-(p-nitrophenethyl)piperazinyl]propyl], and 10-[3-[N-(p-aminophenethyl)piperazinyl]propyl].

L4 ANSWER 18 OF 20 CAPLUS COPYRIGHT 2003 ACS  
 AN 1958:104438 CAPLUS  
 DN 52:104438  
 OREF 52:18502d-i,18503a-b  
 TI N-[(10-Phenothiazinyl)-lower alkyl]-1,5-iminocycloalkanes  
 IN Zenitz, Bernard L.  
 PA Sterling Drug Inc.  
 DT Patent  
 LA Unavailable

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2838505		19580610	US	
IT	119148-95-7, Nortropine, 8-(4-phenothiazin-10-ylbutyl)- 123885-14-3, Nortropine, 8-(4-phenothiazin-10-ylbutyl)-, acetate (prep. of)				
RN	119148-95-7	CAPLUS			
CN	Nortropine, 8-(4-phenothiazin-10-ylbutyl)-	(6CI)	(CA INDEX NAME)		

Relative stereochemistry.



RN 123885-14-3 CAPLUS  
 CN Nortropine, 8-(4-phenothiazin-10-ylbutyl)-, acetate (6CI) (CA INDEX NAME)

Relative stereochemistry.




GI For diagram(s), see printed CA Issue.  
 AB Compds. (I) were prep'd., where Y and Y' are the same or different H, halogen, lower-alkyl, or lower-alkoxy, A is a lower-alkylene group, n is 1 or 2, R is H, and R' is OH, O-Acyl, Cl, Br, or RR' is O. The I are useful

as hypotensive agents, antinauseants, antipyretics, and sedatives. (All m.ps. are cor.). 10-(3-Chloropropyl)phenothiazine (13.8 g.) and 7.1 g. tropine (II) in 25 cc. HCONMe<sub>2</sub> heated 24 hrs. on a steam bath, cooled in an ice bath, dild. with 50 cc. anhyd. Et<sub>2</sub>O, again cooled, the ppt. filtered off, triturated with Me<sub>2</sub>CO, the ppt. filtered off, and recrystd. 1st from 600 cc. iso-PrOH and then twice from 50 cc. abs. EtOH-75 cc. anhyd. Et<sub>2</sub>O with C gave 8.0 g. 8-[3-(10-phenothiazinyl)propyl]-3-hydroxynortropine-MeCl, m. 224.5-5.5 (decompn.). Similarly were prep'd. the following I (R = H in all cases) (Y, Y', A, n, R', m.p. given): H, H, (CH<sub>2</sub>)<sub>2</sub>, 1, OH, - (methochloride, m. 221-3.degree.); H, H, (CH<sub>2</sub>)<sub>2</sub>, 1, OAc, - (methochloride, m. 241-3.degree.); H, H, (CH<sub>2</sub>)<sub>2</sub>, 1, OAc, - (methochloride, m. 232.5-3.5.degree.); H, H, (CH<sub>2</sub>)<sub>2</sub>, 1, OH, 126-8.degree. (HCl salt, m. 246.5-8.5.degree.) [prep'd. by treating II with H<sub>2</sub>O<sub>2</sub> to obtain II oxide (III), m. 228-9.degree., treating III with Ac<sub>2</sub>O to obtain N,O-diacetyl nortropine, and sapong. to nortropine (IV), m. 161-3.degree. (Me<sub>2</sub>CO), and treating with 10-(2-bromoethyl)phenothiazine]; H, H, (CH<sub>2</sub>)<sub>2</sub>, 1, OAc, 114-15.degree.; H, H, (CH<sub>2</sub>)<sub>3</sub>, 1, OH, 87.5-9.0.degree. (HCl salt, m. 177-9.degree.); H, H, (CH<sub>2</sub>)<sub>3</sub>, 1, OAc, 141.0-3.5.degree. (HCl salt, m. 218-20.degree.); H, H, (CH<sub>2</sub>)<sub>3</sub>, 1, O<sub>2</sub>CCH:CHPh, 139.0-41.5.degree.; H, H, (CH<sub>2</sub>)<sub>3</sub>, 1, OBz, 121-2.degree.; H, H, (CH<sub>2</sub>)<sub>4</sub>, 1, OH, 133-7.degree.; H, H, (CH<sub>2</sub>)<sub>4</sub>, 1, OAc, 115.5-18.0.degree.; H, H, (CH<sub>2</sub>)<sub>5</sub>, 1, OH, - (HCl salt, m. 192-4.degree.) [prep'd. from p-MeC<sub>6</sub>H<sub>4</sub>SO<sub>3</sub>(CH<sub>2</sub>)<sub>5</sub>Cl, b<sub>0</sub>.14-0.23 148-53.degree., nD<sub>25</sub> 1.5157, by treating with phenothiazine to obtain 10-(5-chloropentyl)phenothiazine, b<sub>0</sub>.09 157.5-60.0.degree., nD<sub>25</sub> 1.6391, followed by treatment with IV]; 2-Cl, H, (CH<sub>2</sub>)<sub>3</sub>, 1, OH, 119.5-22.0.degree.; 2-Cl, H, (CH<sub>2</sub>)<sub>3</sub>, 1, O<sub>2</sub>CCH:CHPh, 130.5-1.5.degree.; 2-Cl, H, (CH<sub>2</sub>)<sub>3</sub>, 1, OBz, 94.0-8.5.degree.; 2-Cl, H, (CH<sub>2</sub>)<sub>3</sub>, 1, O<sub>2</sub>CC<sub>6</sub>H<sub>2</sub>(OMe)3-3,4,5, 155-8.degree.; 3-Cl, H, (CH<sub>2</sub>)<sub>3</sub>, 1, OH, 146.5-8.5.degree. [prep'd. from p-MeC<sub>6</sub>H<sub>4</sub>SO<sub>3</sub>(CH<sub>2</sub>)<sub>3</sub>Cl, b<sub>0</sub>.04 141-7.degree., nD<sub>25</sub> 1.6660, and (3-chloropropyl)phenothiazine to obtain 3-chloro-10-(3-chloropropyl)phenothiazine, m. 45.0-7.5.degree., and treatment with IV]; 3-Cl, H, (CH<sub>2</sub>)<sub>3</sub>, 1, OAc, 107.5-9.5.degree.; 3-Cl, H, (CH<sub>2</sub>)<sub>3</sub>, 1, OBz, 102.0-4.5.degree.; 3-Cl, H, (CH<sub>2</sub>)<sub>3</sub>, 1, O<sub>2</sub>CCH:CHPh, 114.5-15.5.degree.; 3-Cl, H, (CH<sub>2</sub>)<sub>3</sub>, 1, O<sub>2</sub>CC<sub>6</sub>H<sub>2</sub>(OMe)3-3,4,5, 165.0-6.5.degree.; 2-Cl, H, (CH<sub>2</sub>)<sub>3</sub>, 1, OH, 96.5-101.degree. [prep'd. from pseudonortropine (m. 132-4.degree.) and CO<sub>2</sub> to obtain pseudonortropine carbamate, m. 141-2.degree., followed by treatment with 2-chloro-10-(3-chloropropyl)phenothiazine]. When n is 2 in I, the compds. are derivs. of granatanine.

L4 ANSWER 19 OF 20 CAPLUS COPYRIGHT 2003 ACS  
 AN 1957:73091 CAPLUS  
 DN 51:73091  
 OREF 51:13200a-d  
 TI Structure activity relationships of some phenothiazine-substituted nortropane-derivatives  
 AU Long, J. P.; Lands, A. M.; Zenitz, B. L.  
 CS Sterling-Winthrop Inst., Rensselaer, NY  
 SO J. Pharmacol. Exptl. Therap. (1957), 119, 479-84  
 DT Journal  
 LA Unavailable  
 IT 119148-95-7, Nortropine, 8-(4-phenothiazin-10-ylbutyl)- (pharmacology of)  
 RN 119148-95-7 CAPLUS  
 CN Nortropine, 8-(4-phenothiazin-10-ylbutyl)- (6CI) (CA INDEX NAME)


Relative stereochemistry.




AB A series of 13 nortropane-substituted phenothiazine derivs. were investigated for central-nervous-system activity (production of hypothermia in mice) and peripheral adrenolytic action (reversal of adrenaline effects in dogs). The compds. had a di-, tri-, tetra-, or pentamethylene bridge joining the phenothiazine N with the tropane N and had H, OH, or a 3,4,5-trimethoxybenzoxy radical in the 3-position of the tropane ring. In most respects the adrenolytic activity closely paralleled the central-nervous-system activity. The trans isomers showed higher activity than the cis isomers or the 3-dehydroxy derivs. The exptl. data support the hypothesis that a drug-receptor interaction is involved both centrally and peripherally, and that these receptors are quite similar with respect to the compds. studied. 2-Chloro substitution in the phenothiazine ring increases the central-nervous-system activity without a consistent alteration of the peripheral adrenolytic activity.

L4 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2003 ACS  
 AN 1957:73090 CAPLUS  
 DN 51:73090  
 OREF 51:13199i,13200a  
 TI Pharmacology of carbutamide  
 AU Root, Mary A.  
 CS Lilly Research Labs., Indianapolis, IN  
 SO J. Pharmacol. Exptl. Therap. (1957), 119, 468-78  
 DT Journal  
 LA Unavailable  
 IT 119148-95-7, Nortropine, 8-(4-phenothiazin-10-ylbutyl)-  
     (pharmacology of)  
 RN 119148-95-7 CAPLUS  
 CN Nortropine, 8-(4-phenothiazin-10-ylbutyl)- (6CI) (CA INDEX NAME)

Relative stereochemistry.





AB Carbutamide is a sulfonylurea deriv. with low toxicity which causes hypoglycemia when given orally to normal animals. It is ineffective in alloxan-diabetic animals and in totally depancreatized dogs. If it is administered to diabetic animals being treated with insulin, their blood-glucose concns. and daily urinary sugar excretion are decreased below the levels found with insulin alone.